JPRN-UMIN000004039Completed未知
Randomized Phase II trial of single early intravesical administration of THP for prevention of recurrent bladder tumors following surgery for upper urinary tract urotherial tumors. - THPMG
Tohoku University School of Medicine,Department of Urology0 sites50 target enrollmentStarted: August 13, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
Seventy-two patients were evaluable for efficacy analysis, 21 of whom had a subsequent bladder recurrence. Significantly fewer patients who received THP had a recurrence compared with the control group (16.9% at 1 year and 16.9% at 2 years in the THP group v 31.8% at 1 year and 42.2% at 2 years in the control group; log-rank P = .025). No remarkable adverse events were observed in the THP-treated group.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)The patient having a grave complication 2) Active cancer except upper urinary tract urotherial tumors is the patient 3)In addition, the patient whom we intended for it, and it was judged judgment of a doctor to be inadequate
Investigators
Similar Trials
Active, not recruiting
Phase 1
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG TreatmentUrinary Bladder NeoplasmsImmunotherapyNCT04706598Fudan University25
Completed
Phase 2
stekinumab in adolescents with recent-onset type 1 diabetesNutritional, Metabolic, EndocrineType 1 diabetes mellitusISRCTN14274380Cardiff University88
Completed
Phase 1
Two institutional trial to evaluate the feasibility and efficacy of combined adjuvant therapy with gemcitabine and cisplatin for biliary tract cancerBiriary tract cancerJPRN-UMIN000001294Chiba Cancer Center30
Completed
Phase 2
A Phase II Clinical Trial of Nedaplatin and Amurubicin Therapy for Advanced and Recurrent Squamous Cell Lung Cancer.squamous cell Lung carcinomaJPRN-UMIN000007587agasaki Thoracic Oncology Group21
Completed
Phase 2
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type PsoriasisPsoriasisNCT00320216Centocor, Inc.320